Kyle Ring, Melanie Smuk, Moses Shongwe, Leroy Okonta, Nicola E Mackie, Sara Ayres, Tristan J Barber, Jane Akodu, Filippo Ferro, Daniella Chilton, Eliot Hurn, Bhavna Halai, Will Barchi, Asim Ali, Sandra Darko, Gemma White, Emily Clarke, Fiona Clark, Bazga Ali, Joseph Arumainayagam, Gaynor Quinn, Marta Boffito, Ruth Byrne, Nadia Naous, Suki Leung, Athavan Umaipalan, Brian Thornton, David Bayliss, Catherine McLoughlin, Jonathan Foster, Laura Waters, Chloe Orkin
{"title":"对英国 12 家诊所注射用卡博替拉韦和利匹韦林的交付和结果进行多中心服务评估（SHARE LAI-net）。","authors":"Kyle Ring, Melanie Smuk, Moses Shongwe, Leroy Okonta, Nicola E Mackie, Sara Ayres, Tristan J Barber, Jane Akodu, Filippo Ferro, Daniella Chilton, Eliot Hurn, Bhavna Halai, Will Barchi, Asim Ali, Sandra Darko, Gemma White, Emily Clarke, Fiona Clark, Bazga Ali, Joseph Arumainayagam, Gaynor Quinn, Marta Boffito, Ruth Byrne, Nadia Naous, Suki Leung, Athavan Umaipalan, Brian Thornton, David Bayliss, Catherine McLoughlin, Jonathan Foster, Laura Waters, Chloe Orkin","doi":"10.1111/hiv.13679","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Long-acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics.</p><p><strong>Methods: </strong>Centres populated a database using information from local policies and clinical records. Services were asked to describe approval processes, clinic pathways, and adherence to national guidelines. Additional data were collected on reasons for regimen choice, treatment discontinuations, and management of viraemia.</p><p><strong>Results: </strong>In total, 518 adults from 12 clinics were approved for CAB + RPV LAI between February 2022 and December 2023. Of the 518 people approved for CAB + RPV LAI, 423 received at least one injection. Median duration on CAB + RPV was 7.5 months (interquartile range 3.7-11.3). In total, 97% of injections were administered within the ±7-day window. Virological failure occurred in 0.7%, and 6% discontinued CAB + RPV.</p><p><strong>Conclusion: </strong>In this large UK-based cohort, robust approval processes and clinic protocols facilitated on-time injections and low rates of both discontinuation and virological failure.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net).\",\"authors\":\"Kyle Ring, Melanie Smuk, Moses Shongwe, Leroy Okonta, Nicola E Mackie, Sara Ayres, Tristan J Barber, Jane Akodu, Filippo Ferro, Daniella Chilton, Eliot Hurn, Bhavna Halai, Will Barchi, Asim Ali, Sandra Darko, Gemma White, Emily Clarke, Fiona Clark, Bazga Ali, Joseph Arumainayagam, Gaynor Quinn, Marta Boffito, Ruth Byrne, Nadia Naous, Suki Leung, Athavan Umaipalan, Brian Thornton, David Bayliss, Catherine McLoughlin, Jonathan Foster, Laura Waters, Chloe Orkin\",\"doi\":\"10.1111/hiv.13679\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Long-acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics.</p><p><strong>Methods: </strong>Centres populated a database using information from local policies and clinical records. Services were asked to describe approval processes, clinic pathways, and adherence to national guidelines. Additional data were collected on reasons for regimen choice, treatment discontinuations, and management of viraemia.</p><p><strong>Results: </strong>In total, 518 adults from 12 clinics were approved for CAB + RPV LAI between February 2022 and December 2023. Of the 518 people approved for CAB + RPV LAI, 423 received at least one injection. Median duration on CAB + RPV was 7.5 months (interquartile range 3.7-11.3). In total, 97% of injections were administered within the ±7-day window. Virological failure occurred in 0.7%, and 6% discontinued CAB + RPV.</p><p><strong>Conclusion: </strong>In this large UK-based cohort, robust approval processes and clinic protocols facilitated on-time injections and low rates of both discontinuation and virological failure.</p>\",\"PeriodicalId\":13176,\"journal\":{\"name\":\"HIV Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/hiv.13679\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/hiv.13679","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net).
Introduction: Long-acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics.
Methods: Centres populated a database using information from local policies and clinical records. Services were asked to describe approval processes, clinic pathways, and adherence to national guidelines. Additional data were collected on reasons for regimen choice, treatment discontinuations, and management of viraemia.
Results: In total, 518 adults from 12 clinics were approved for CAB + RPV LAI between February 2022 and December 2023. Of the 518 people approved for CAB + RPV LAI, 423 received at least one injection. Median duration on CAB + RPV was 7.5 months (interquartile range 3.7-11.3). In total, 97% of injections were administered within the ±7-day window. Virological failure occurred in 0.7%, and 6% discontinued CAB + RPV.
Conclusion: In this large UK-based cohort, robust approval processes and clinic protocols facilitated on-time injections and low rates of both discontinuation and virological failure.
期刊介绍：
HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
